Rovin Capital Bristol Myers Squibb CO Transaction History

Rovin Capital

$244 Million
Q1 2024

A detailed history of Rovin Capital transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Rovin Capital holds 5,324 shares of BMY stock, worth $211,149. This represents 0.12% of its overall portfolio holdings.

Number of Shares

5,324

Holding current value

$211,149

% of portfolio

0.12%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 22, 2024	BUY	$47.98 - $54.4 $255,445 - $289,625	5,324 New	5,324 $289,000
Q1 2023 Apr 05, 2023	SELL	$65.71 - $74.53 $1,117 - $1,267	-17 Reduced 0.57%	2,945 $204,000
Q4 2022 Jan 23, 2023	SELL	$68.48 - $81.09 $3,150 - $3,730	-46 Reduced 1.53%	2,962 $213,000
Q3 2022 Oct 25, 2022	SELL	$0.13 - $76.84 $14 - $8,375	-109 Reduced 3.5%	3,008 $214,000
Q2 2022 Jul 22, 2022	SELL	$72.62 - $79.98 $327,734 - $360,949	-4,513 Reduced 59.15%	3,117 $240,000

Q1 2022 Jun 13, 2022	SELL	$61.48 - $73.72 $240,079 - $287,876	-3,905 Reduced 33.85%	7,630 $557,000
Q4 2021 Feb 24, 2022	BUY	$53.63 - $62.52 $618,622 - $721,168	11,535 New	11,535 $719,000

Others Institutions Holding BMY

# of Institutions

2,553

Shares Held

1.49B

Call Options Held

25.9M

Put Options Held

20M

Vanguard Group Inc Valley Forge, PA

186M
Shares

$7.38 Billion
0.2% of portfolio
Black Rock Inc. New York, NY

163M
Shares

$6.45 Billion
0.21% of portfolio
State Street Corp Boston, MA

91.6M
Shares

$3.63 Billion
0.23% of portfolio
Jpmorgan Chase & CO New York, NY

88.8M
Shares

$3.52 Billion
0.44% of portfolio
Capital International Investors Los Angeles, CA

70.2M
Shares

$2.78 Billion
0.79% of portfolio

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $84.3B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rovin Capital , based on Form 13F filings with the SEC.

News

Stay updated on Rovin Capital with notifications on news.

Account